bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 8 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Prevalence of MET tyrosine kinase domain (TKD) mutations across cancer types in cohort #2.
Table S1 from Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
Authors: Matusiak Magdalena , Hickey John W. , van IJzendoorn David G.P. , Lu Guolan , Kidziński Lukasz , Zhu Shirley , Colburg Deana R.C. , Luca Bogdan , Phillips Darci J. , Brubaker Sky W. , Charville Gregory W. , Shen Jeanne , Loh Kyle M. , Okwan-Duodu Derick K. , Nolan Garry P. , Newman Aaron M. , West Robert B. , van de Rijn Matt
Published: August 2024

Supplementary Table 1. List of IHC antibodies
Supplementary Table 6 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Prevalence of MET tyrosine kinase domain (TKD) mutations across cancer types in cohort #1.
Supplementary Table 5 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

List of missense mutations with unknown biologic function and their pathogenicity scores using all three in silico tools in cohorts #2
Figure S8 from Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
Authors: Matusiak Magdalena , Hickey John W. , van IJzendoorn David G.P. , Lu Guolan , Kidziński Lukasz , Zhu Shirley , Colburg Deana R.C. , Luca Bogdan , Phillips Darci J. , Brubaker Sky W. , Charville Gregory W. , Shen Jeanne , Loh Kyle M. , Okwan-Duodu Derick K. , Nolan Garry P. , Newman Aaron M. , West Robert B. , van de Rijn Matt
Published: August 2024

This Figure shows Kaplan-Meier plots of CRC patient samples stratified by IL4I1+ macrophage counts.
Supplementary Table 4 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

List of missense mutations with unknown biologic function and their pathogenicity scores using all three in silico tools in cohort #1
Figure S7 from Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
Authors: Matusiak Magdalena , Hickey John W. , van IJzendoorn David G.P. , Lu Guolan , Kidziński Lukasz , Zhu Shirley , Colburg Deana R.C. , Luca Bogdan , Phillips Darci J. , Brubaker Sky W. , Charville Gregory W. , Shen Jeanne , Loh Kyle M. , Okwan-Duodu Derick K. , Nolan Garry P. , Newman Aaron M. , West Robert B. , van de Rijn Matt
Published: August 2024

Thus Figure shows spatial enrichment of NLRP3+ macrophages with neutrophils in Crohn’s Disease, and immunostimulatory and immunosuppressive protein marker expression in NLRP3+ vs SPP1+ macrophages.
Supplementary Table 26 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Mutagenic primers used for mutagenesis.
Supplementary Table 19 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Detailed clinicopathologic and genomic characteristics related to renal cell cancer cases in cohort #1.
Supplementary Table S2 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Authors: Lei Guang , Mao Chao , Horbath Amber D. , Yan Yuelong , Cai Shirong , Yao Jun , Jiang Yan , Sun Mingchuang , Liu Xiaoguang , Cheng Jun , Xu Zhihao , Lee Hyemin , Li Qidong , Lu Zhengze , Zhuang Li , Chen Mei-Kuang , Alapati Anagha , Yap Timothy A. , Hung Mien-Chie , You Mingjian James , Piwnica-Worms Helen , Gan Boyi
Published: August 2024

Supplementary table S2 shows relevant gene mutation information for the cell lines and xenografts
Supplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Authors: Lei Guang , Mao Chao , Horbath Amber D. , Yan Yuelong , Cai Shirong , Yao Jun , Jiang Yan , Sun Mingchuang , Liu Xiaoguang , Cheng Jun , Xu Zhihao , Lee Hyemin , Li Qidong , Lu Zhengze , Zhuang Li , Chen Mei-Kuang , Alapati Anagha , Yap Timothy A. , Hung Mien-Chie , You Mingjian James , Piwnica-Worms Helen , Gan Boyi
Published: August 2024

Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
Supplementary Table 18 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Detailed clinicopathologic and genomic characteristics of the 61 cases with a malignancy other than NSCLC harboring an oncogenic / likely oncogenic MET TKD mutation in cohort #1.
Supplementary Table 14 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Concurrent genomic drivers in cases with oncogenic / likely oncogenic MET tyrosine kinase domain (TKD) mutations and co-occurring MET gene amplification in cohort #2.
Supplementary Table 1 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Supplementary Table 1. Prevalence of MET tyrosine kinase domain (TKD) mutations in each dataset of the cohort #1.
Supplementary Methods from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Additional information regarding the methods used in this study
Supplementary Figure 8 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Concurrent oncogenic driver alterations according to specific oncogenic / likely oncogenic MET TKD mutations detected in NSCLC cases (N=129) of cohort #2.
Table S3 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Authors: Xu Yaru , Yang Yuqiu , Wang Zhaoning , Sjöström Martin , Jiang Yuyin , Tang Yitao , Cheng Siyuan , Deng Su , Wang Choushi , Gonzalez Julisa , Johnson Nickolas A. , Li Xiang , Li Xiaoling , Metang Lauren A. , Mukherji Atreyi , Xu Quanhui , Tirado Carla R. , Wainwright Garrett , Yu Xinzhe , Barnes Spencer , Hofstad Mia , Chen Yu , Zhu Hong , Hanker Ariella B. , Raj Ganesh V. , Zhu Guanghui , He Housheng H. , Wang Zhao , Arteaga Carlos L. , Liang Han , Feng Felix Y. , Wang Yunguan , Wang Tao , Mu Ping
Published: August 2024

Table S3. Significantly Enriched or Depleted Signaling Pathways in GSEA Analysis
Supplementary Figure 7 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Genomic characterization of NSCLC harboring oncogenic / likely oncogenic MET TKD mutations in cohort #1 and #2. Genomic characteristics of 44 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations from cohort #1: (A) concurrent driver alterations and (B) concurrent MET amplification status (information unavailable for 4 cases). Genomic characteristics of 129 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations from cohort #2: (C) concurrent driver alterations and (D) concurrent MET amplification status.
Supplementary Figure 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Overview of MET TKD mutations detected in pan-cancer cohorts. (A) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in the cohort #1 (711 MET TKD mutations among 664 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (B) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #1. (C) Distribution of MET TKD mutations across MET kinase domain for cohort #1. (D) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in cohort #2 (2,559 MET TKD mutations among 2,477 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (E) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #2. (F) Distribution of MET TKD mutation across MET kinase domain for cohort #2.
Supplementary Figure 15 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

In vitro analysis of MET H1094Y and F1200I mutations in PC9 cells. (A) Establishment of NSCLC cancer cell lines expressing MET TKD mutations. PC9 cells were transduced with wild-type (WT) MET (as control) and MET H1094Y and F1200I. (B) Growth inhibition assay of PC9 cells in response to EGFR inhibition with osimertinib. (C) Cell proliferation and relative apoptosis were monitored under EGFR inhibition with osimertinib (300 nM). (D) Phosphorylation of MET, EGFR, AKT, and ERK was analyzed in PC9 cells expressing MET TKD mutants. PC9 cells were treated with osimertinib (1 μM) with or without capmatinib (1 μM) for 48 hrs. (E) IC50 values of PC9 cells (upper table) and Ba/F3 cells (lower table) expressing MET TKD mutants in response to MET TKIs. PC9 cells were treated with gradient dose of MET TKI combined with a fixed dose of osimertinib (100 nM) for 72 hrs.
Supplementary Figure 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Growth inhibition assays of Ba/F3 cells expressing MET TKD mutants under treatment with MET TKIs.
Supplementary Figure 11 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

In vitro analysis of “probably benign” MET TKD mutations in Ba/F3 cells. (A) Phosphorylation of MET was analyzed in Ba/F3 cells stably transduced with MET TKD mutants. MET H1094Y and F1200I were included as positive controls for oncogenic mutations (OncoKB, also detected in the two patient cases) and MET WT was included as negative control. (B) IL-3-independent cell proliferation of Ba/F3 cells expressing “probably benign” MET TKD mutants, shown by relative spheroid size measured daily from day 1 to day 7. (C) Spheroid images of Ba/F3 cells expressing MET TKD mutants taken on day 1 and day 7.
Table S2 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Authors: Schoenfeld Adam J. , Lee Sylvia M. , Doger de Spéville Bernard , Gettinger Scott N. , Häfliger Simon , Sukari Ammar , Papa Sophie , Rodríguez-Moreno Juan F. , Graf Finckenstein Friedrich , Fiaz Rana , Catlett Melissa , Chen Guang , Qi Rongsu , Masteller Emma L. , Gontcharova Viktoria , He Kai
Published: August 2024

T-cell phenotypic marker comparison between responders and non-responders
Figure S5 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Authors: Schoenfeld Adam J. , Lee Sylvia M. , Doger de Spéville Bernard , Gettinger Scott N. , Häfliger Simon , Sukari Ammar , Papa Sophie , Rodríguez-Moreno Juan F. , Graf Finckenstein Friedrich , Fiaz Rana , Catlett Melissa , Chen Guang , Qi Rongsu , Masteller Emma L. , Gontcharova Viktoria , He Kai
Published: August 2024

IOV-COM-202 patient treatment schema. CY, cyclophosphamide; EOA, end of assessment; EOS, end of study; EOT, end of treatment; FLU, fludarabine; GMP, Good Manufacturing Practice; NMA-LD, nonmyeloablative lymphodepletion; TIL, tumor-infiltrating lymphocytes.
Figure S2 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Authors: Schoenfeld Adam J. , Lee Sylvia M. , Doger de Spéville Bernard , Gettinger Scott N. , Häfliger Simon , Sukari Ammar , Papa Sophie , Rodríguez-Moreno Juan F. , Graf Finckenstein Friedrich , Fiaz Rana , Catlett Melissa , Chen Guang , Qi Rongsu , Masteller Emma L. , Gontcharova Viktoria , He Kai
Published: August 2024

Adverse Events Over Time
Supplementary Table S7 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Authors: Chen Lishu , Qi Qinghui , Jiang Xiaoqing , Wu Jin , Li Yuanyuan , Liu Zhaodan , Cai Yan , Ran Haowen , Zhang Songyang , Zhang Cheng , Wu Huiran , Cao Shuailiang , Mi Lanjuan , Xiao Dake , Huang Haohao , Jiang Shuai , Wu Jiaqi , Li Bohan , Xie Jiong , Qi Ji , Li Fangye , Liang Panpan , Han Qiuying , Wu Min , Zhou Wenchao , Wang Chenhui , Zhang Weina , Jiang Xin , Zhang Kun , Li Huiyan , Zhang Xuemin , Li Ailing , Zhou Tao , Man Jianghong
Published: August 2024

Supplementary Table S7 shows the primer sequences used for Real-Time PCR.
Supplementary Table S4 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Authors: Chen Lishu , Qi Qinghui , Jiang Xiaoqing , Wu Jin , Li Yuanyuan , Liu Zhaodan , Cai Yan , Ran Haowen , Zhang Songyang , Zhang Cheng , Wu Huiran , Cao Shuailiang , Mi Lanjuan , Xiao Dake , Huang Haohao , Jiang Shuai , Wu Jiaqi , Li Bohan , Xie Jiong , Qi Ji , Li Fangye , Liang Panpan , Han Qiuying , Wu Min , Zhou Wenchao , Wang Chenhui , Zhang Weina , Jiang Xin , Zhang Kun , Li Huiyan , Zhang Xuemin , Li Ailing , Zhou Tao , Man Jianghong
Published: August 2024

Supplementary Table S4 shows PCr and BRD2 IHC staining scores in the serial sections of human glioma microarrays.
Supplementary Notes from St. Jude Survivorship Portal: Sharing and Analyzing Large Clinical and Genomic Datasets from Pediatric Cancer Survivors
Authors: Matt Gavriel Y. , Sioson Edgar , Shelton Kyla , Wang Jian , Lu Congyu , Zaldivar Peraza Airen , Gangwani Karishma , Paul Robin , Reilly Colleen , Acić Aleksandar , Liu Qi , Sandor Stephanie R. , McLeod Clay , Patel Jaimin , Wang Fan , Im Cindy , Wang Zhaoming , Sapkota Yadav , Wilson Carmen L. , Bhakta Nickhill , Ness Kirsten K. , Armstrong Gregory T. , Hudson Melissa M. , Robison Leslie L. , Zhang Jinghui , Yasui Yutaka , Zhou Xin
Published: August 2024

Supplementary Notes
Supplementary Figure S7 from St. Jude Survivorship Portal: Sharing and Analyzing Large Clinical and Genomic Datasets from Pediatric Cancer Survivors
Authors: Matt Gavriel Y. , Sioson Edgar , Shelton Kyla , Wang Jian , Lu Congyu , Zaldivar Peraza Airen , Gangwani Karishma , Paul Robin , Reilly Colleen , Acić Aleksandar , Liu Qi , Sandor Stephanie R. , McLeod Clay , Patel Jaimin , Wang Fan , Im Cindy , Wang Zhaoming , Sapkota Yadav , Wilson Carmen L. , Bhakta Nickhill , Ness Kirsten K. , Armstrong Gregory T. , Hudson Melissa M. , Robison Leslie L. , Zhang Jinghui , Yasui Yutaka , Zhou Xin
Published: August 2024

User interface for genetic association analysis on the portal
Supplementary Table S1 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Authors: Chen Lishu , Qi Qinghui , Jiang Xiaoqing , Wu Jin , Li Yuanyuan , Liu Zhaodan , Cai Yan , Ran Haowen , Zhang Songyang , Zhang Cheng , Wu Huiran , Cao Shuailiang , Mi Lanjuan , Xiao Dake , Huang Haohao , Jiang Shuai , Wu Jiaqi , Li Bohan , Xie Jiong , Qi Ji , Li Fangye , Liang Panpan , Han Qiuying , Wu Min , Zhou Wenchao , Wang Chenhui , Zhang Weina , Jiang Xin , Zhang Kun , Li Huiyan , Zhang Xuemin , Li Ailing , Zhou Tao , Man Jianghong
Published: August 2024

Supplementary Table S1 shows PCr IHC staining score in human glioma microarray.
Supplementary Figure S5 from St. Jude Survivorship Portal: Sharing and Analyzing Large Clinical and Genomic Datasets from Pediatric Cancer Survivors
Authors: Matt Gavriel Y. , Sioson Edgar , Shelton Kyla , Wang Jian , Lu Congyu , Zaldivar Peraza Airen , Gangwani Karishma , Paul Robin , Reilly Colleen , Acić Aleksandar , Liu Qi , Sandor Stephanie R. , McLeod Clay , Patel Jaimin , Wang Fan , Im Cindy , Wang Zhaoming , Sapkota Yadav , Wilson Carmen L. , Bhakta Nickhill , Ness Kirsten K. , Armstrong Gregory T. , Hudson Melissa M. , Robison Leslie L. , Zhang Jinghui , Yasui Yutaka , Zhou Xin
Published: August 2024

Scatter plot and complete regression results measuring the association between mental health, amputation, and age
Data from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Authors: Pecci Federica , Nakazawa Seshiru , Ricciuti Biagio , Harada Guilherme , Lee Jessica K. , Alessi Joao V. , Barrichello Adriana , Vaz Victor R. , Lamberti Giuseppe , Di Federico Alessandro , Gandhi Malini M. , Gazgalis Dimitris , Feng William W. , Jiang Jie , Baldacci Simon , Locquet Marie-Anaïs , Gottlieb Felix H. , Chen Monica F. , Lee Elinton , Haradon Danielle , Smokovich Anna , Voligny Emma , Nguyen Tom , Goel Vikas K. , Zimmerman Zachary , Atwal Sumandeep , Wang Xinan , Bahcall Magda , Heist Rebecca S. , Iqbal Sumaiya , Gandhi Nishant , Elliott Andrew , Vanderwalde Ari M. , Ma Patrick C. , Halmos Balazs , Liu Stephen V. , Che Jianwei , Schrock Alexa B. , Drilon Alexander , Jänne Pasi A. , Awad Mark M.
Published: August 2024

Abstract
Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling among >600,000 patients, we identify activating MET TKD point mutations as putative oncogenic driver across diverse cancers, with a frequency of ∼0.5%. The most common mutations in the MET TKD defined as oncogenic or likely oncogenic according to OncoKB resulted in amino acid substitutions at positions H1094, L1195, F1200, D1228, Y1230, M1250, and others. Preclinical modeling of these alterations confirmed their oncogenic potential and also demonstrated differential patterns of sensitivity to type I and type II MET inhibitors. Two patients with metastatic lung adenocarcinoma harboring MET TKD mutations (H1094Y, F1200I) and no other known oncogenic drivers achieved confirmed partial responses to a type I MET inhibitor. Activating MET TKD mutations occur in multiple malignancies and may confer clinical sensitivity to currently available MET inhibitors.

Significance: The identification of targetable genomic subsets of cancer has revolutionized precision oncology and offers patients treatments with more selective and effective agents. Here, we demonstrate that activating, oncogenic MET tyrosine kinase domain mutations are found across a diversity of cancer types and are responsive to MET tyrosine kinase inhibitors.
Data from Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
Authors: Matusiak Magdalena , Hickey John W. , van IJzendoorn David G.P. , Lu Guolan , Kidziński Lukasz , Zhu Shirley , Colburg Deana R.C. , Luca Bogdan , Phillips Darci J. , Brubaker Sky W. , Charville Gregory W. , Shen Jeanne , Loh Kyle M. , Okwan-Duodu Derick K. , Nolan Garry P. , Newman Aaron M. , West Robert B. , van de Rijn Matt
Published: August 2024

Abstract
Tumor-associated macrophages are transcriptionally heterogeneous, but the spatial distribution and cell interactions that shape macrophage tissue roles remain poorly characterized. Here, we spatially resolve five distinct human macrophage populations in normal and malignant human breast and colon tissue and reveal their cellular associations. This spatial map reveals that distinct macrophage populations reside in spatially segregated micro-environmental niches with conserved cellular compositions that are repeated across healthy and diseased tissue. We show that IL4I1+ macrophages phagocytose dying cells in areas with high cell turnover and predict good outcome in colon cancer. In contrast, SPP1+ macrophages are enriched in hypoxic and necrotic tumor regions and portend worse outcome in colon cancer. A subset of FOLR2+ macrophages is embedded in plasma cell niches. NLRP3+ macrophages co-localize with neutrophils and activate an inflammasome in tumors. Our findings indicate that a limited number of unique human macrophage niches function as fundamental building blocks in tissue.

Significance: This work broadens our understanding of the distinct roles different macrophage populations may exert on cancer growth and reveals potential predictive markers and macrophage population-specific therapy targets.
Data from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Authors: Lei Guang , Mao Chao , Horbath Amber D. , Yan Yuelong , Cai Shirong , Yao Jun , Jiang Yan , Sun Mingchuang , Liu Xiaoguang , Cheng Jun , Xu Zhihao , Lee Hyemin , Li Qidong , Lu Zhengze , Zhuang Li , Chen Mei-Kuang , Alapati Anagha , Yap Timothy A. , Hung Mien-Chie , You Mingjian James , Piwnica-Worms Helen , Gan Boyi
Published: August 2024

Abstract
Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) limits the therapeutic efficacy of PARP inhibition in treating breast cancer susceptibility gene 1 (BRCA1)-deficient cancers. Here we reveal that BRCA1 has a dual role in regulating ferroptosis. BRCA1 promotes the transcription of voltage-dependent anion channel 3 (VDAC3) and glutathione peroxidase 4 (GPX4); consequently, BRCA1 deficiency promotes cellular resistance to erastin-induced ferroptosis but sensitizes cancer cells to ferroptosis induced by GPX4 inhibitors (GPX4i). In addition, nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy and defective GPX4 induction unleash potent ferroptosis in BRCA1-deficient cancer cells upon PARPi and GPX4i co-treatment. Finally, we show that xenograft tumors derived from patients with BRCA1-mutant breast cancer with PARPi resistance exhibit decreased GPX4 expression and high sensitivity to PARP and GPX4 co-inhibition. Our results show that BRCA1 deficiency induces a ferroptosis vulnerability to PARP and GPX4 co-inhibition and inform a therapeutic strategy for overcoming PARPi resistance in BRCA1-deficient cancers.

Significance:BRCA1 deficiency promotes resistance to erastin-induced ferroptosis via blocking VDAC3 yet renders cancer cells vulnerable to GPX4i-induced ferroptosis via inhibiting GPX4. NCOA4 induction and defective GPX4 further synergizes GPX4i with PARPi to induce ferroptosis in BRCA1-deficient cancers and targeting GPX4 mitigates PARPi resistance in those cancers.

See related commentary by Alborzinia and Friedmann Angeli, p. 1372
O novo marco paranaense da inovação: avanços e retrocessos em termos de conceitos e princípios
Authors: Verde Lucas Henrique Lima , Miranda João Irineu de Resende
Published: August 2024

This paper looks at the relationship between the Paraná's State Innovation System and the National ST&I System, given the most recent developments in the state. The aim is to find out to what extent the new ST&I Framework for Paraná innovates and goes beyond the mere reproduction of its federal counterpart, in terms of principles and conceptual delimitations. The method employed is deductive, using bibliographical and indirect documentary research. It was concluded that the scope of the state law is more extensive, even in programmatic directions, it is not completely disruptive, but it adds coherence and consistency to the whole, favoring more complex arrangements and giving more permissibility to numerous provisions. Even so, there are possible setbacks, due to ambiguities, duplication of resources or conflicting regulations, and the drafting of the framework is partial progress, since there is no guarantee of effective implementation and efficient results.
Formação de jurisprudência administrativa pela ANPD: estudo de casos das sanções aplicadas
Authors: Oliveira Kátia Adriana Cardoso de
Published: August 2024

This article aims to analyze the administrative assessments applicable by the General Data Protection Law (LGPD) and regulated by the National Data Protection Authority (ANPD), highlighting the first sanction applied by the authority due to a violation of the LGPD. The methodology involves bibliographical research, using LGPD provisions and legal and technical instruments modified by the ANPD as primary sources. This approach included an in-depth analysis of the assessments and their regulatory context, highlighting the guidelines determined by the Authority for their application. Furthermore, analysis of the first sanction applied by the authority offers insights into how Brazil is protecting individuals' privacy rights. In conclusion, the LGPD and the ANPD's actions represent innovative advances in protecting the privacy and personal data of Brazilian citizens. Administrative sanctions play a crucial role in ensuring compliance with the provisions of the law, promoting greater responsibility on the part of organizations and encouraging a culture of data protection.
19. Relationships between humans and lions in wildlife corridors through CBNRM in north-west Namibia
Authors: Muzuma Uakendisa
Published: August 2024

Protected areas are considered essential for conserving large carnivores, although large carnivores also occur outside protected areas and have shared landscapes with humans for millennia. The Namibian Community-Based Natural Resources Management programme adopted in 1996 aims to devolve wildlife conservation practices and to benefit local people inhabiting communal areas. The programme is experiencing challenges, but has achieved some success in encouraging the coexistence of wildlife and rural communities on communal land. Because the programme is built upon human wildlife coexistence, however, human- lion conflict is also present. This has been a pressing concern, particularly regarding people’s willingness to coexist with dangerous animals such as lions. From a wildlife conservation perspective, a lack of monitoring of human settlement and livestock movement into conservancy areas zoned for wildlife is a concern. This chapter discusses current research from remote sensing of lion and goat movement using satellite- Global Positioning System collars, focusing on understanding goat movement ecology within designated wildlife areas. Information collected on goat movements within wildlife areas will be used to better manage the shared landscape in the perceived “corridor” between Etosha National Park and the Skeleton Coast National Park. The research shared here thus focuses on the “ lion- goat space”, contributing to evidence-based goat spatial habitat use in communal area conservancies to ensure appropriate deployments of human- lion conflict mitigation measures.
Efficacy of Nano-Silver Dressing Combined with Silver Sulfadiazine Cream in the Treatment of Second-Degree Burn Wounds
Authors: He Qianfeng , Lin Lin , Jiang Wei , Qu Huanmin , Zhang Yani , Zhao Congying , Yuan Yacui , Li Hailang , Jiang Wan , Du Baoping
Published: August 2024

This study investigates the clinical efficacy of nanosilver dressing combined with silver sulfadiazine cream (SSC) in the treatment of second-degree burn wounds. A total of 100 patients with second-degree burns admitted to our hospital from January 2022 to March 2023 were selected.
The patients were randomly divided into a control group (n = 50) and an observation group (n = 50). The control group used SSC, while the observation group used nanosilver dressings based on the control group. The incidence of complications, clinical efficacy, wound healing rate,
bacterial culture positive rate, pigmentation clearance time, and inflammatory factor levels before and after treatment were analyzed in the two groups. We observed a significantly higher total effective rate in the observation group (97%) compared to the control group (88%). The incidence
of complications was significantly lower in the observation group (10%) than in the control group (64%). Additionally, we found that the wound healing rate was higher and wound healing time was shorter in the observation group compared to the control group. The pigmentation clearance time
was significantly shorter in the observation group. After treatment, the levels of inflammatory factors TNF-α, IL-6, and CRP were significantly lower in the observation group compared to those in the control group. Moreover, we observed a significantly lower bacterial culture
positive rate and pain intensity in the observation group compared to the control group. Overall, this combined application provides a safe and effective option for treating second-degree burn wounds.
Misrepresenting Methodology: A Critique of Epistemological Engineering in Social Science Research
Authors: Prasad Ajnesh , Li Eric Ping Hung
Published: August 2024

Among the most pervasive issues currently debated in the social sciences pertains to scientific misconduct. The discourse on scientific misconduct has burgeoned in the last three decades and has come to permeate multiple arenas, including academia, industry, and public policy. While interest in this area has imparted critical insights into understanding and regulating the phenomenon, some commentators have argued that it is time to expand the scope of what acts precisely qualify as scientific misconduct—beyond its conventional definition that conflates the term with fabrication, falsification, and plagiarism. In responding to this line of critique, this article focuses on a neglected aspect of scientific misconduct, though one which is particularly prevalent in social science research—namely, the case of researchers offering disingenuous claims related to a study's methodology. To explicate how this form of misconduct in science materializes into action, this article revisits Bruno Latour's careful tracing of scientists in laboratories. Through his analysis, Latour captures the disjuncture in the rhetoric and the practice of methodology in empirical research. Integrating Latour's critique with the concept of agential realism, we present one philosophically grounded avenue by which to resolve this form of scientific misconduct in future social science research.
Determining the residual volume in peritoneal dialysis using low molecular weight markers
Authors: Lindholm Elin , Martus Giedre , Öberg Carl M , Bergling Karin
Published: August 2024

Background

Variation in residual volume between peritoneal dialysis dwells creates uncertainty in ultrafiltration determination, dialysis efficiency, and poses a risk of overfill if the residual volume is large. Measuring the dilution of a marker molecule during fluid fill offers a convenient approach, however, estimation accuracy depends on the choice of dilution marker. We here evaluate the feasibility of creatinine and urea as dilution markers compared to albumin-based residual volumes and three-pore model estimations.

Method

This clinical, retrospective analysis comprises 56 residual volume estimations from 20 individuals, based on the dilution of pre-fill dialysate creatinine, urea and albumin concentrations during the dialysis fluid fill phase. Outcomes were compared individually. Bias induced by ultrafiltration, marker molecule mass-transfer and influence of fluid glucose contents was quantified using the three-pore model. Linear regression established conversion factors enabling conversion between the various marker molecules.

Results

Creatinine-based calculations overestimated residual volumes by 115 mL (IQR 89–149) in 1.5% dwells and 252 mL (IQR 179–313) in 4.25% glucose dwells. In hypertonic dwells, ultrafiltration was 52 mL (IQR 38–66), while intraperitoneal creatinine mass increased by 67% during fluid fill, being the leading cause of overestimation. Albumin-based volumes conformed strongly with three-pore model estimates. Correction factors effectively enabled marker molecule interchangeability.

Conclusions

Mass-transfer of low molecular weight marker molecules is associated with residual volume overestimation. However, by applying correction factors, creatinine and urea dilution can still provide reasonable estimates, particularly when the purpose is to exclude the presence of a very large residual volume.
Understanding the kynurenine pathway: A narrative review on its impact across chronic pain conditions
Authors: Hazrati Ebrahim , Eftekhar Seyed Parsa , Mosaed Reza , Shiralizadeh Dini Saeed , Namazi Mehrshad
Published: August 2024

Chronic pain is a debilitating symptom with a significant negative impact on the quality of life and socioeconomic status, particularly among adults and the elderly. Major Depressive Disorder (MDD) stands out as one of the most important comorbid disorders accompanying chronic pain. The kynurenine pathway serves as the primary route for tryptophan degradation and holds critical significance in various biological processes, including the regulation of neurotransmitters, immune responses, cancer development, metabolism, and inflammation. This review encompasses key research studies related to the kynurenine pathway in the context of headache, neuropathic pain, gastrointestinal disorders, fibromyalgia, chronic fatigue syndrome, and MDD. Various metabolites produced in the kynurenine pathway, such as kynurenic acid and quinolinic acid, exhibit neuroprotective and neurotoxic effects, respectively. Recent studies have highlighted the significant involvement of kynurenine and its metabolites in the pathophysiology of pain. Moreover, pharmacological interventions targeting the regulation of the kynurenine pathway have shown therapeutic promise in pain management. Understanding the underlying mechanisms of this pathway presents an opportunity for developing personalized, innovative, and non-opioid approaches to pain treatment. Therefore, this narrative review explores the role of the kynurenine pathway in various chronic pain disorders and its association with depression and chronic pain.
Self-rated health and its bidirectional relationship with burnout, sleep quality and somatic symptoms in a general adult population
Authors: Nordin Maria , Sundström Anna , Hakelind Camilla , Nordin Steven
Published: August 2024

The aim of this study was to investigate how self-rated health (SRH) reflects ongoing ill-health and how SRH is associated with previous ill-health and/or predicts future ill-health such as burnout, disturbed sleep, and somatic symptoms. The study used two waves from the population-based Västerbotten Environmental and Health Study in which 2 336 adult persons participated by answering a questionnaire at two time points three years apart. Hierarchical and logistic regression analyses were conducted, thus treating all variables both continuously (degree) and categorically (case). The analyses were performed both cross-sectionally and longitudinally. The results showed bidirectionality between suboptimal SRH and burnout, disturbed sleep and somatic severity caseness. Moreover, degree of poor SRH was more likely to occur simultaneously to high degrees of burnout and somatic severity than to degree of poor sleep quality. Also, caseness of burnout, disturbed sleep and somatic severity increased the risk of simultaneous suboptimal SRH. Finally, the results showed that degree of burnout three years earlier, predicted degree of poor SRH, and that degree of poor SRH predicted degree of sleep three years later. In conclusion, in a population-based, normal adult sample there is a bidirectional relationship between suboptimal SRH and caseness of burnout, disturbed sleep quality and somatic symptoms, but not between degree of these symptoms. The results can have implications for health care meeting patients complaining about poor general health.